Serda Therapeutics

Serda Therapeutics company information, Employees & Contact Information

SERDA Therapeutics is a joint venture between Smith & Nephew and NLC, focused on developing innovative wound care solutions. The company is dedicated to bringing to market a proprietary, best-in-class, fast-acting therapeutic product for burn injuries and chronic ulcers. SERDA has completed a Phase 1 Safety and Tolerability study in July 2024. This study was a blinded, randomized study that examined the immediate and 21-day cumulative irritation potential of ascending enzyme concentrations in SN514 hydrogel. The results confirm best-in-class potential for SN514 as the protection of “periwound” skin is unlikely to be necessary in clinical use. SERDA is initiating its Phase 1b clinical study in Q4 2024 in patients with burn wounds, a major unmet clinical need in battlefield applications and natural disasters. This clinical development program is also supported by the US Department of Defense with a grant of $2.5 million. SERDA is raising €15 million to complete its Phase 2 clinical programs in Burn and chronic Pressure Injury

Company Details

Employees
1
Founded
-
Address
Paasheuvelweg 25, Amsterdam,1105 Bp,netherlands
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Amsterdam
Looking for a particular Serda Therapeutics employee's phone or email?

Serda Therapeutics Questions

Top Serda Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant